- Report
- December 2023
- 80 Pages
Russia
From €1349EUR$1,500USD£1,155GBP
- Report
- December 2023
- 80 Pages
Saudi Arabia
From €1349EUR$1,500USD£1,155GBP
- Report
- December 2023
- 80 Pages
South Korea
From €1349EUR$1,500USD£1,155GBP
- Report
- December 2023
- 80 Pages
United States
From €1349EUR$1,500USD£1,155GBP
- Report
- December 2023
- 80 Pages
Vietnam
From €1349EUR$1,500USD£1,155GBP
- Report
- January 2024
- 116 Pages
Global
From €3500EUR$4,168USD£3,100GBP
- Report
- May 2023
- 90 Pages
Global
From €3500EUR$4,168USD£3,100GBP
- Report
- January 2021
- 146 Pages
China, Global
From €3000EUR$3,572USD£2,657GBP
- Report
- October 2023
- 114 Pages
Global
From €3500EUR$4,168USD£3,100GBP
- Report
- October 2023
- 140 Pages
Global
From €3500EUR$4,168USD£3,100GBP
- Report
- December 2022
- 69 Pages
Global
From €1799EUR$2,000USD£1,540GBP
- Book
- July 2023
- 1568 Pages
- Book
- July 2015
- 328 Pages

Amphotericin B is an antifungal drug used to treat a variety of fungal infections, including those caused by Candida, Aspergillus, and Cryptococcus species. It is commonly used to treat systemic fungal infections, such as those affecting the lungs, heart, and central nervous system. It is also used to treat fungal infections of the skin, nails, and eyes. Amphotericin B is a polyene macrolide antibiotic, and is the most commonly used antifungal drug in the world. It is available in both intravenous and oral formulations, and is often used in combination with other antifungal drugs.
The Amphotericin B market is a subset of the larger Infectious Diseases Drugs market. It is a highly competitive market, with a number of companies offering Amphotericin B products. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and AstraZeneca. Show Less Read more